CTXR Stock Overview
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy.
Citius Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.18|
|52 Week High||US$2.01|
|52 Week Low||US$0.83|
|1 Month Change||15.69%|
|3 Month Change||-5.60%|
|1 Year Change||-35.87%|
|3 Year Change||126.97%|
|5 Year Change||-74.65%|
|Change since IPO||-92.13%|
Recent News & Updates
Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAKSep 28
Citius Pharmaceuticals GAAP EPS of -$0.06Aug 11
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash WiselyAug 05
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business GrowthDec 04
Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In GrowthAug 28
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business GrowthMay 15
Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?Dec 18
|CTXR||US Pharmaceuticals||US Market|
Return vs Industry: CTXR underperformed the US Pharmaceuticals industry which returned 15% over the past year.
Return vs Market: CTXR underperformed the US Market which returned -17.6% over the past year.
|CTXR Average Weekly Movement||6.5%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CTXR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CTXR's weekly volatility (6%) has been stable over the past year.
About the Company
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals, Inc. Fundamentals Summary
|CTXR fundamental statistics|
Is CTXR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CTXR income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.21|
|Net Profit Margin||0.00%|
How did CTXR perform over the long term?See historical performance and comparison